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ABSTRACT: The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, 
as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types 
of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the 
main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how 
these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications 
of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target 
the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of 
broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned 
societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which 
will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and 
education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/
national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion 
involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach. 
(Hypertension. 2021;77:1029-1035. DOI: 10.1161/HYPERTENSIONAHA.120.16340.) • Data Supplement
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The General Data Protection Regulation (GDPR) became binding law in all European Union (EU) Member States in May 2018.1,2 As a Regulation, it is, 
in principle, directly applicable to all EU Member States, 
superseding existing Member State laws. It, thus, rep-
resents a significant step toward harmonizing EU data 
protection laws.3
The GDPR applies to the processing of personal data 
across a large range of contexts, including those used in 
biomedical research and pertaining to vast areas of transla-
tional and clinical research activities, although it was proba-
bly not drafted with all the latter purposes in mind. As such, 
it has instigated multiple discussions among researchers 
and, in several cases, has raised major concerns, par-
ticularly, but not exclusively, in the genomics community 
(reviewed in study by Townend,3 Phillips,4 and Hallinan5).
With the present intense need for international scien-
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major publishers and research funders,6,7 GDPR require-
ments, particularly with respect to specific consent for 
data and bio-sample sharing, generate confusion and 
uncertainty and create conflicts between Regulation 
and Research Ethics.8 Under the fear of legal and social 
sanctions in combination with the threat of huge penal-
ties as a consequence of violating GDPR, scientists have 
become reluctant to exchange data and bio-samples for 
secondary research.9 Increasingly, data and bio-sample 
use is restricted (to eg, specific hospitals, research insti-
tutions, or regions). In addition, the basic principle of sci-
entific publishing that all relevant research data must be 
made accessible to ensure transparency and data reuse 
is frequently violated. Public health emergencies (such 
as the Ebola and Zika virus outbreaks and especially the 
ongoing coronavirus disease 2019 [COVID-19] pan-
demic) exemplify the need to facilitate swift and safe 
data sharing around the globe, without legal delays.10,11
This article aims to review the main principles of 
GDPR, in particular, pertinent to consent, as related to 
biomedical research; in this context, it discusses the 
practical problems related to data and bio-sample shar-
ing, currently encountered by researchers, perceived to 
be linked directly or indirectly to GDPR; it also provides 
suggestions for interpretations and potential adaptations 
of the Regulation to better fit the practical realities of 
current biomedical research.
CONSENT AND PERSONAL DATA IN THE 
GDPR
Focusing on the most relevant issues, basic definitions 
and major aspects of the Regulation with direct impact 
on biomedical research are summarized in Table 1.
Processing of personal data concerning health is a 
priori prohibited (Article 9). Exemptions can be made 
based on consent which, as shown (Table 1), involves 
a clear, affirmative action in GDPR (Article 4.11). This 
action cannot simply be assumed based on failure to 
opt-out (eg, by not refusing preticked boxes or default 
settings). In addition, the scope of consent covers data 
processing for one or more specific purposes (Article 6). 
“Specific” is not explicitly defined but interpretations sug-
gest that “the objectives of research, the principal inves-
tigator and the project’s duration are specified”.12
Exceptions allowing research without consent exist, 
based on Member State law for “archiving purposes in 
the public interest, scientific or historical research pur-
poses” (Articles 6, 9). Alternatively, there is the possibility 
of obtaining consent for purposes not fully specified in 
advance (what we would call “broad” consent), related 
to “certain areas of scientific research, when in keeping 
with recognized ethical standards” (Recital 33). Never-
theless, there is confusion about the extent for which 
these exceptions could be applicable.13
Both directly identifiable and pseudonymized data 
used by researchers should be treated as personal data 
(Table 1), based on the presumed residual risk of research 
subject identification, in case of pseudonymization (sum-
marized in study by Rumbold and Pierscionek14). Anony-
mized data are not affected or regulated by GDPR. To 
ensure anonymization, simply changing the identity label 
is insufficient. Multiple techniques are existent for further 
data perturbation to avoid (re) identification based on the 
variables listed.15
CURRENT STATUS IN BIOMEDICAL 
RESEARCH DATA AND BIO-SAMPLE 
SHARING
Sharing is an undisputed ethical obligation of any inves-
tigator (including those conducting patient-centered 
research) and is a prerequisite for scientific and clinical 
advancement.16 To frame this basic condition, pertinent 
ethical norms exist, including study monitoring by inde-
pendent ethics committees, aiming to protect human 
subjects, while at the same time, promoting research col-
laboration (for a historical perspective, see study by Phil-
lips4). The need for sharing in research becomes even 
more obvious and critical, when studying rare diseases 
(such as rare cardiac diseases17), which requires com-
pilation of resources to allow meaningful research. In 
addition, and regardless of the disease incidence rates, 
Nonstandard Abbreviations and Acronyms
COVID-19 coronavirus disease 2019
EU European Union
GDPR The General Data Protection Regulation
Table 1. Basic GDPR Definitions Relevant to Personal Data
Personal data: any information relating to an identified or identifiable natural 
person (data subject) (Article 4[1] of the GDPR). In practical terms, the 
definition covers all types of data and information, which have some connec-
tion to a specific, identifiable person. The connection can exist (1) on the 
basis of the content of the data or information itself—for example, in the case 
of biometric identifiers—or (2) on the basis of the possibility of combining 
data with other data sets, which would allow a connection to be made to a 
specific individual.
Pseudonymous data: data that have been produced via pseudonymization 
(Article 4(5) of the GDPR). The latter means the processing of personal data 
in such a manner that the personal data can no longer be attributed to a 
specific data subject, without the use of additional information, provided that 
such additional information is kept separate. Practically, pseudonymization 
involves coding of data. Pseudonymous data are still considered personal 
(Recital 26).
Anonymous data: data from which no connection to a specific identifiable 
person can be drawn, based on either the specific data alone or through 
linking to other datasets. Anonymous data fall outside applicability of the 
GDPR (Recital 26).
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the increasing diversity and complexity of molecular 
profiles and pathophysiologic phenotypes, underscores 
the need for adopting a systems integrative approach to 
define associations and causes, and, ultimately, biology-
driven biomarkers and therapeutic targets. As an exam-
ple, meta-analysis of genome-wide association datasets 
enables the identification of cardiovascular or kidney 
disease risk factors or confounders, that are too rare 
to be revealed at the individual study level.18,19 Likewise, 
fueling artificial intelligence algorithms with sufficiently 
large, multi-level datasets (clinical, pathophysiologi-
cal, imaging, molecular), offers the unique opportunity 
to understand disease in a holistic manner.20,21 Along 
the same lines, data linkage can lead to better disease 
predictors, which was recently shown of particular value 
in stroke research.22 Such large scale holistic analyses 
can only be realized via data sharing and data reuse and 
are actively supported by major medical associations 
(eg reflected in the establishment of standards for data 
collection by the American Heart Association/American 
College of Cardiology Task Force on Data Standards21) 
and research funders, such as the EU Framework Pro-
gram Horizon 2020, the National Institutes of Health, 
United States, and others.
GDPR-triggered restrictions linked to the require-
ments for specific consent generate uncertainty and 
slow down or even prohibit research activities. Contribut-
ing to this problem are the exponential developments in 
molecular technologies, which allow high resolution mul-
tidimensional analyses of a biological sample, making it 
hard or even impossible in the case of high-resolution 
genetic information, to truly anonymize study partici-
pants.13,23 Having to comply with an extensive (88 pages) 
legal framework increases the need for legal advice. As 
a result, collectively, valuable data and clinical samples 
may remain unused or significantly underused, causing a 
decrease of the power of the analyses.
To receive guidance on this critical issue of data and 
bio-sample use and sharing, as linked to study partici-
pant consent requirements in the context of the GDPR, 
several relevant translational networks (eg, the Euro-
pean Uremic Toxin Work Group [EuTox—https://www.
uremic-toxins.org/], the European Society of Urologic 
Research [ESUR; https://uroweb.org/section/esur/
information/], the Clinical Biomarkers COST Action 
[CliniMark; https://clinimark.eu/], and the International 
Bladder Cancer Network [IBCN; http://ibcnweb.net/]), 
initiated a discussion on the topic.
REFLECTIONS ON IMPLEMENTING 
GDPR IN SCIENTIFIC DATA AND SAMPLE 
SHARING
The main questions/problems currently distressing 
researchers and respective answers deduced from the 
Regulation and discussions with legal experts are sum-
marized in Table 2.
The answers provided (Table 2) highlight some 
main impediments perceived to be directly or indirectly 
imposed by the GDPR on biomedical research data and 
bio-sample sharing:
(1) Although the initial aim of the GDPR was to har-
monize practices in the EU Member States, hence facili-
tating data sharing, a significant part of decision-making 
is still left to the Member States, increasing confusion 
and bureaucratic complexity. As a consequence, imple-
mentation of multinational collaborative projects relying 
on data and bio-sample sharing and mobility frequently 
face de facto regulatory deadlocks, which in our expe-
rience, to the least, slow down progress. Even more 
restrictions apply in the case of research involving part-
ners outside the EU (including collaborations with Euro-
pean countries, Japan, or the United States), requiring a 
“lawful basis for making the transfer”.9
(3) Consent to data use ensuring protection of partici-
pants, undoubtedly constitutes a pillar of clinical research 
ethics and the principal condition to obtain ethical 
approval. However, the stated need for specific consent 
raises doubts as to the legitimacy of the use of valu-
able stored data and bio-samples covered by pre-GDPR 
consent forms. Calling for national regulation to legiti-
mate processing, when the specific consent is not fully 
available or cannot be readily obtained, opens Pandora’s 
box in terms of the complexity of the legal landscape. 
The high complexity in relation to the scope of consent is 
illustrated by the problems that arise when existing data 
and bio-samples collected with the purpose of identifying 
specific biomarkers, for instance, for cardiovascular dis-
ease, would be considered as control in a study target-
ing the identification of specific chronic kidney disease 
biomarkers. In the absence of an explicit specification of 
this latter prospect in the original consent referring to 
cardiovascular disease, the use of such data and sam-
ples in chronic kidney disease research may be, a priori, 
prohibited. A possibility may exist to allow reuse with a 
supplemental consent. If this is not possible, reuse may 
be possible if a relevant national law has been enacted. 
However, in this latter case, use of Member State law 
to legitimate processing may end up causing issues in 
cases of collaborations requiring cross-border data and 
bio-sample exchange involving multiple EU Member 
States, as national laws do not always align.
(3) A potential solution in the latter case could be the 
use of data and bio-samples in an anonymized manner, 
hence, being exempt from GDPR and (re) consent require-
ments. However, considering the frequent availability of 
multiparametric, clinical, pathological, and molecular data 
characterizing a study participant, as mentioned above, it 
is reasonable to assume that true anonymization is only 
possible at the cost of significant loss of information (per-
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Big Data analyses.13,23 Furthermore, anonymization may 
be incompatible with many current research objectives 
(such as study of disease progression in a longitudinal, 
individualized manner, as required to establish treatment 
in a personalized approach).
SOLUTIONS
Specification of the impediments forms the basis for 
a fruitful discussion toward resolution or improvement. 
Potential ways forward might include (summarized in 
Table 3) the following:
(1) Similar to other areas in medicine,25 public/gen-
eral population education and engagement in research 
pipelines is critical. This would target getting a clear 
understanding of the definitions and associated benefits 
and risks with broad and other emerging forms of con-
sent, namely meta-consent (allowing the research par-
ticipant to define what type, when and how consent 
may be provided in the future26) or dynamic consent 
(through web platforms27). In addition, it would explain 
residual risks for reidentification. There is an apparent 
ever increasing willingness of individuals to share their 
data for research advancement, reflected in the exis-
tence of large personal genome projects (such as the 
Harvard or Canadian, United Kingdom, Austrian, Korean, 
and other national personal genome projects; https://
www.personalgenomes.org/). Interactions of research-
ers and patients should be intensified in the form of 
large patient-linked networks (for example, the Euro-
pean Kidney Health Alliance; involving Kidney Patients 
and Foundations, Nephrologists and Nurses, http://
ekha.eu/; or the US National Patient-Centered Clinical 
Research Network [PCORnet]), consisting of health care 
centers, as well as patient organizations (Patient-Pow-
ered Research Networks; https://pcornet.org/patient-
centric/), and via regular local outreach initiatives led 
by academic health centers, with the aim of achieving 
patient-centered informed consent, anticipating as much 
as possible future developments.
(2) Addressing issues related to secondary use of 
data and need for respective re-consent is the most 
challenging problem, as, for the time being, this seems 
to be in many cases subject to national law. In our opin-
ion, this cannot be solved by an ad hoc administrative, 
legal, or policy change only; it must be the topic of a 
broad multidisciplinary discussion involving researchers, 
patient advocacy groups and the general public, eth-
ics experts, regulators, and politicians targeting clarity 
and harmonization, as much as possible going beyond 
national boundaries, in line with the international char-
acter of high-level research. An example in this direction 
forms the design of the Final Rule, the latest update of 
the federal policy for the protection of human subjects 
in the United States, which emerged after being subject 
to commenting by the general public, various agencies, 
and expert stakeholders.28 Our proposal is that the lead 
to open this discussion is taken by a Consortium of sev-
eral acknowledged societies involved in the field, includ-
ing patient advocacy groups; these should work closely 
with relevant authorities at the EU level (EU Directorate 
General [DG] for Research and Innovation, the European 
Commissioner for Research, Innovation and Science, 
and the Committee of Members of European Parliament 
for Industry, Research and Energy), and eventually also 
involve the respective national authorities, toward har-
monizing interpretations of the law, aiming at minimizing 
boundaries impeding cross-border research in the EU.
(3) In this context, the generation of a standard-
ized consent form (broad consent allowing generic 
future research activities), acceptable to all stakehold-
ers involved, would be of enormous benefit. Such efforts 
Table 2. Main Practical Questions-Concerns of Researchers 
and Respective Answers Deduced From the GDPR
Question Answer
(1) Can data be shared and 
reused after publication?
Yes, if the prospect of data sharing and fur-
ther use was included in the original consent 
form.
If not specified in the original consent, excep-
tions may be allowed depending on the 
inability for re-consenting.
Obtaining legitimation for exceptions can be 
complex and will be governed by the GDPR 
(Articles 9[2][i], [g], and [j]) and the national 
laws of individual Member States.
(2) Can follow-up (monitor-
ing over time) data be used 
and shared?
Yes, if the research participant has specifi-
cally consented.
Exceptions may be applicable, as above 
(point 1).
(3) Can biobanked data and 
bio-samples be shared and 
used?
A positive or negative response by default is 
not possible. It depends on the specifics of 
the situation.9
Issue relates to the use of data and samples 
in broad fields of research, regularly linked to 
broad consent. GDPR does not use the term 
broad consent; but is also not entirely oppos-
ing to the concept of broad use (Recital 33).
Major existing international biobanking instru-
ments are supportive of broad consent (eg, 
the World Medical Association [WMA] Dec-
laration of Taipei).
National laws (potentially applicable under 
the GDPR Articles 9[2][j], or Article 9[4]) 
frequently differ in their requirements for data 
and sample use from biobanks.
(4) Are data and bio-sample 
restrictions to specific 
researchers/institutes 
allowed by the GDPR?
Not addressed by the GDPR.
Issue relates to privacy and data and bio-
sample ownership with divergent views in 
different countries.24
(5) How can we generate 
anonymized data for further 
sharing?
Multiple anonymization techniques exist 
depending on the type of identifiers and 
dimension of the dataset.15
Anonymization requires well trained person-
nel; with awareness of the subject matter 
and individual importance of each data field.
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in the case of biobanking do exist, for example, in Ger-
many,12 but should be expanded on a harmonized Euro-
pean (and, possibly, international) level. Such a form 
should inform research participants that complete ano-
nymization may not always be feasible (eg, in the case of 
whole genome sequencing) and that pseudonymization 
will be applied to minimize risk for reidentification. As a 
step in this direction, a template consent form, using a 
multi-omics study as a test case, is provided (Data Sup-
plement). This is adapted from, and borrows text from 
existing consent forms (Health Innovation and Research 
Institute from the Ghent University Hospital, Belgium29; 
and Human Cancer Models Initiative, United States30). 
This form is intended to serve as a basis for discussion 
with ethics/legal experts and research participants-
patient representatives for further improvement (includ-
ing abbreviating and simplifying to obtain a legally and 
ethically sound template, that meets the needs of both 
research participants and researchers).
(4) The frequently observed restriction of data and 
bio-samples to specific institutions or countries, although 
not instructed by GDPR, is often the consequence of 
fear of violating GDPR. Basic research ethics through 
implementation of FAIR principles (Findable, Accessible, 
Interoperable, and Reusable data16) and compliance with 
privacy and data protection principles should be observed 
and can be monitored, as recently described.31 Systems, 
such as DATAshield, for simultaneous analysis of multi-
source individual data without actual data transfer,32 
data hubs allowing highly regulated access,3 or block-
chain platforms offering de-centralised data access and 
interoperability,33 provide data sharing solutions which 
help maintaining data integrity and patient security. Both 
the patient and scientific communities would benefit 
from a harmonized European roadmap on this issue.
CONCLUSIONS
The collective experience accrued by now renders the 
time ripe to assess whether or not the GDPR is on 
the right track with respect to scientific data and bio-
sample sharing and facilitating adherence to the basic 
research ethics of data sharing. Although, in principle, 
the GDPR is a step toward regulatory harmonization, 
based on the issues presented above, adjustments are 
urgently needed. These should (1) increase harmoni-
zation by minimizing differences caused by exceptions 
based on national laws; (2) seek explicit endorsement 
of the concept of broad consent and consequently; (3) 
better define the roadmap for secondary use of data 
and bio-samples at European (and, if possible, inter-
national) level. The lead to formulate the working draft 
should be taken by a team of acknowledged learned 
societies in the field including patient advocacy groups 
working closely with experts at the EU level; finalization 
should be made following a period of commenting by a 
broad multi-stakeholder audience. This process should 
evolve in parallel to promoting engagement and edu-
cation of the public in the relevant definitions (of, eg, 
broad [specific, meta-, or dynamic] consent; data shar-
ing; residual risk for re-identification), led by academic 
health centers on a local level and amplified by large 
patient-centered multidisciplinary networks. We hope 
that this article will serve as a catalyst for this broad 
discussion involving all major stakeholders, toward opti-
mizing GDPR to facilitate biomedical research and to 
produce social benefit and welfare.
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to Member States, 
increasing bureaucratic 
complexity. Restrictions 
on multinational EU (and 
international) data and 




based on national 
law should be 
restricted/eliminated 
and harmonization 




A document outlining 
optimal interpretations of 
the GDPR should be pre-
pared by acknowledged 
learned societies in the 
field, working closely with 
relevant authorities and 
patient groups; the draft 
will be subjected to com-
menting by representatives 
of all involved stakeholders 
(patients, regulators, legal 
officers, scientists) before 
finalization.
Apparent need for 
specific consent com-
plicates or prohibits 
secondary data use.
Obtain explicit 
endorsement for the 
concept of broad 
consent and other 
emerging consent 
forms (such as 
meta- or dynamic 
consent).
Education of the general 
public on different forms 
of consent and associated 
risks should be intensified 
locally (via activities led 
by local academic health 
centers) and internationally 
(via large patient-centered 
networks). The general 
public should be actively 
involved in finalizing 









Fear for violating GDPR 





ciples) with privacy 
and data protection 
principles.
A harmonized roadmap 
for safe data sharing and 
monitoring compliance to 
privacy and data protec-
tion principles using state 
of the art tools should be 
defined.
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